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Efficacy of HPA Lanolin® in treatment of lip 
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The side effects of chemotherapy on the lips may cause esthetic and functional impact and increase the risk of infection. HPA Lanolin® is an option for supportive therapy because 
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undergoing chemotherapy. Material and Methods: Patients undergoing chemotherapy 
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control (without supportive therapy on the lips). We evaluated the patients two weeks 
after chemotherapy, registering oral alterations, symptoms of pain, discomfort, limitation 
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Patients who used HPA Lanolin® had lower dehydration and experienced improvement of 
lip dryness (p<0.001). The main symptoms were dehydration, discomfort, limitation of 
mouth opening, pain. The main clinical signs were dry lips, mucositis, cheilitis, hematoma, 
swelling and cracking. We found no difference concerning the variables of pain, discomfort, 
and limitation of mouth opening between the study and control group. Conclusions: We 
suggest that HPA Lanolin® is effective in reducing the symptoms of dehydration and the 
signs of lip dryness resulting from toxicity of chemotherapy, proving to be an interesting 
alternative supportive therapy for cancer patients.
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INTRODUCTION
Lip alterations related to cancer treatment 
represent 32.5% to 46% of the oral manifestations 
that occur due to the toxicity of chemotherapy4-6. 
The chemotherapeutic agents themselves can 
cause a rupture of the lips, bleeding, ulceration, 
and this has an impact on the quality of life of 
cancer patients. It increases the risk of systemic 
dissemination of bacteria from the mouth, which 
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infections9-11,16.
The main chemotherapy agents whose toxicity 
is related to the onset of oral lesions are the 
following: Actinomycin D, Amsacrine, Bleomycin, 
Cytarabine, Daunorrubicin, Doxatel, Doxorubicin, 
Etoposide, Floxuridine, 5-Fluoracil, Methotrexate, 
Mitoxantrone, Primacine, Tioguanine, Vinblastine, 
Vindesine and Melphalan9. These agents deserve 
special attention for the doctor of dental surgery 
(DDS) for the diagnosis and monitoring of oral 
lesions.
For proper oral care during chemotherapy, 
meticulous attention should be paid to the lips 
because they are an external contact area that 
can be a port for bacteria. One of the options for 
supportive therapy for the lips of patients undergoing 
chemotherapy is topical lanolin ointment, which can 
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be applied to the lips as often as necessary to keep 
them moist, and it has a low risk of side effects. The 
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anticancer treatment has been cited as an option 
to prevent and to treat lip lesions12-14, but there 
are no studies in the literature about the use of lip 
products for cancer patients.
Lanolin is a natural wax obtained from sheep 
wool grease, and it has different degrees of purity. 
Its composition is of high structural complexity, 
mixing high molecular weight esters. Lanolin is a 
unique product without substitutes, and it has a 
low allergenic capacity. This composition helps it 
to absorb water, making it an excellent moisturizer, 
as well as having excellent adherence10. There 
is great concern in dermatology about contact 
dermatitis and allergic conditions in patients using 
lanolin for skin and lips3,17. The HPA Lanolin® (high 
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and it is considered to be the purest of lanolin. It 
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and protective effects on the epithelium. The 
purification process removes impurities and 
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and bleaches. The absence of these impurities 
results in fewer reports of allergic reactions1,15.
There are very few prospective studies about 
the involvement of the lips in chemotherapy side 
effects. Although some articles quote a statement 
about lanolin lip moisturizer as an option as well, 
currently there is no prospective study in the 
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when applied to the lips of cancer chemotherapy 
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HPA Lanolin® in the prevention of lip alterations in 
a population of patients undergoing chemotherapy.
MATERIAL AND METHODS
 
After receiving approval from the Amaral 
Carvalho Foundation Research Ethics Committee, 
we examined 57 patients undergoing chemotherapy 
with drugs that carry a high risk of developing oral 
mucositis. We excluded patients with a history 
of allergies to HPA Lanolin®. All patients signed 
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and calibration of four dental examiners, the 57 
participants were distributed into two patient 
groups, study (SG) and control (CG). Patients 
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to their lips 6 times/day from the beginning of 
chemotherapy until two weeks after the end of 
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did not use HPA Lanolin®. When necessary, patients 
received an oral care regimen to treat oral mucositis 
with low laser level therapy and rinse solutions with 
an enzymatic system (Biotène®).
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chemotherapy and two weeks after the end of 
chemotherapy, according to the period of HPA 
Lanolin® use, examining the mouth, classifying 
existing lesions according to the presence or 
absence of clinical aspects of dry lips, classifying 
oral mucositis according to the criteria of the World 
Health Organization (WHO)19, and registering 
symptoms of pain, discomfort, sense of limitation 
of mouth opening, and dehydration, classified 
according to a visual analogue scale. The results 
were analyzed with the SPSS statistical software 
package, applying the Shapiro-Wilkes and Mann-
Whitney tests.
RESULTS
We included 57 patients, 27 men (47.7%) and 
30 women (52.6%), with a median age of 58 (17-
38). The SG group, with 25 patients, applied HPA 
Lanolin® to the lips, and the CG group, with 32 
patients, did not apply the product. There were no 
missing data.
Several results of the study are presented here 
in graphic format. They include the symptoms 
reported by patients two weeks after the end 
of chemotherapy (Figure 1), when we might 
see dehydration, discomfort, sense of limitation 
of mouth opening and pain less frequency in 
patients that used the product. The clinical signs 
of alterations caused by chemotherapy (Figure 
2) were dry lips, mucositis, cheilitis, hematoma, 
swelling and cracking.
We examined the efficacy of HPA Lanolin® 
in the reduction of lip symptoms resulting from 
chemotherapy with the Mann-Whitney test, and we 
found a difference between the CG and SG groups 
only in the variable of dehydration (p<0.001). 
Regarding mucositis, even with the use of lanolin, 
60% of patients from the SG presented signs of oral 
mucositis, probably due to the history of previous 
ulcers caused by chemotherapy. The oral mucositis 
scoring by the WHO scale showed in the study group 
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Figure 1- Symptoms of 57 patients undergoing 
chemotherapy. SG, Study Group; CG, Control Group
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We found no difference in the variables of 
pain, discomfort, and limitation of mouth opening 
between the two groups of patients. All these 
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(p>0.05). Although there was no significant 
difference in lip dryness, we observed that patients 
in the SG (40%) group had less dry mouth than 
those in the CG (71.9%) (Figure 2).
DISCUSSION
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of HPA Lanolin® in the prevention of lip alterations in 
a population of patients undergoing chemotherapy. 
We showed that lip dryness and dehydration due 
to chemotherapy can be alleviated with the use 
of HPA Lanolin®. The maintenance of a protective 
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lubrication and protection of the lips. Therefore, 
we can also deduce that lip dryness was reduced, 
preventing other conditions such as erosions and 
ulcers, which could lead the patient to a more 
severe clinical status, such as poor nutrition and 
more severe infections18.
There are no studies related to the use of HPA 
Lanolin® as a treatment for the oral side effects 
of chemotherapy, or for other oral alterations not 
related to chemotherapy, so there are no protocols 
in place for the topical lip product. However, HPA 
Lanolin® has proven effective in preserving the 
integrity of the nipples and areolas in mothers who 
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while breastfeeding, showing lower rates of trauma 
and pain1. It has also been found effective in the 
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lanolin cream in the perianal area twice a day2.
HPA Lanolin® was also important in reducing lip 
dryness and discomfort. The moisturizing property 
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of moisture, may explain the attenuation of lip 
dryness, because the emulsification facilitates 
the transport of water to the deeper layers of 
the epithelium1,7. This product can be used as 
supportive therapy for cancer patients, reducing 
some of the painful side effects of chemotherapy, 
since there are no contraindications for its use. 
This product is easily applied, well tolerated and 
contributes to the comfort of the patient during the 
critical period of chemotherapy. The elimination of 
the impurities and allergenic components of the HPA 
Lanolin® enhances its safety for this use over other 
products with similar properties1,15 such as Vaseline® 
(petroleum jelly) and mineral oil. While these other 
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dryness, they should be avoided because they 
are associated with the aspiration of particles of 
lipids and pneumonia. Moreover Vaseline® is highly 
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receiving oxygen therapy because on the risk of 
burns of face8.
Based on the results of our study, we suggest 
that HPA Lanolin® is effective in reducing the 
symptoms of dehydration and the signs of lip 
dryness resulting from toxicity of chemotherapy 
without side effects. Further studies are necessary 
!)*+,® 
in the prevention of lip alterations of patients 
undergoing chemotherapy.
ACKNOWLEDGMENTS
Z '  
 
interest or external funding for this research.
REFERENCES
1- Abou-Dakn M, Fluhr JW, Gensch M, Wockel A. Positive effect of 
HPA Lanolin versus expressed breastmilk on painful and damaged 
nipples during lactation. Skin Pharmacol Physiol. 2010;24:27-35.
Q	 |}}~ | K   , !   
!
a prospective, randomized, controlled clinical trial. Surg Today. 
2010;40:752-6.
3- Castanedo-Tardan MP, Zug KA. Patterns of cosmetic contact 
allergy. Dermatol Clin. 2009;27:265-80.
4- Chen C, Wang R, Cheng S, Chang Y. Assessment of 
chemotherapy-induced oral complications in children with cancer. 
J Pediat Oncol Nurs. 2004;21:33-9.
5- Chen HM. Patient’s experiences and perceptions of chemotherapy-
induced oral mucositis in a day unit. Care Nursing. 2008;31:363-9.
6- Cowen D, Tarideu C, Schubert M, Peterson D, Resbeut M, 
Faucher C, et al. Low energy Helium-Neon laser in the prevention 
of oral mucositis in patients undergoing bone marrow transplant: 
results of a double blind randomized trial. Int J Radiat Oncol Biol 
Phys. 1997;38:697-703.
7- Hagen RL. Lanolin for sore nipples. Arch Pediatr Adolesc Med. 
1999;153(9):658.
8- Kennedy L, Diamond J. Assessment and management of 
chemotherapy-induced mucositis in children. J Pediat Oncol Nurs. 
1997;14:164-74.
Figure 2- Stomatologic alterations in 57 patients 
undergoing chemotherapy. SG, Study Group; CG, Control 
Group
HKKHLQ'U))	;		HK			Q
2013;21(2):163-6
J Appl Oral Sci. 166
9- Köstler Wj, Hejna M, Wenzel C, Zielinski CC. Oral mucositis 
complicating chemotherapy and/or radiotherapy: options for 
prevention and treatment. CA Cancer J Clin. 2001;51:290-315.
10- Sandoval RL, Koga DH, Buloto LS, Suzuki R, Dib LI. 
Management of chemo- and radiotherapy induced oral mucositis 
with low-energy laser: initial results of A.C. Camargo Hospital. J 
Appl Oral Sci. 2003;11(4):337-41.
11- Santos PSS, Coracin FL, Barros JCA, Dulley FL, Nunes 
FD, Magalhães MG. Impact of oral care prior to HSCT on the 
severity and clinical outcomes of oral mucositis. Clin Transplan. 
2011;25:325-8.
12- Santos PSS, Mesaggi AC, Montesso A, Magalhães MHCG. Oral 
mucositis: recent perspectives on prevention and treatment. Rev 
Gauch Odontol. 2009;57:339-44.
13- Schubert MM, Peterson DE, Lloid ME. Oral complications. 
In: Thomas ED, Blume KG, Forman SJ, ed. Hematopoietic cell 
transplantation. 2nd ed. Malden, MA, Blackwell Science; 2005. 
p.751-63.
14- Semba SE, Mealy BL, Hallmon WW. Dentistry and the cancer 
patient: Part 2 - oral health management of the chemotherapy 
patient. Compend. 1994;15:1378-87.
15- Tanchev S, Vulkova S, Georgieva V, Gesheva I, Tsvetkov M. 
Lansinoh in the treatment of sore nipples in breastfeeding women. 
Akush Ginekol. 2004;43(Suppl 3):27-30.
16- Tolentino ES, Centurion BS, Ferreira LHC, Souza AP, Damante 
JH, Rubira-Bullen IRF. Oral adverse effects of head and neck 
radiotherapy: literature review and suggestion of a clinical oral care 
guideline for irradiated patients. J Appl Oral Sci. 2011;19:448-54.
17- Wakelin SH, Smith H, White IR, Rycroft RJ, McFadden JP. A 
retrospective analysis of contact allergy to lanolin. Br J Dermatol. 
2001;145:28-31.
18- Watters AL, Epstein JB, Agulnik M. Oral complications of 
targeted cancer therapies: a narrative literature review. Oral 
Oncol. 2011;47:441-8.
19- World Health Organization. Handbook for reporting results of 
cancer treatment. Geneva: The Organization; 1979.
@(*
@B
®D
@"

GD
G"*
2013;21(2):163-6
